These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39228080)

  • 1. Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model.
    Mohammed A; Ramadan A; Elnour AA; Saeed AAAM; Al Mazrouei N; Alsulami FT; Alqarni YS; Menon V; Amoodi AA; Abdalla SF
    CNS Neurosci Ther; 2024 Sep; 30(9):e70025. PubMed ID: 39228080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
    Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
    Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear translocation of STAT5 initiates iron overload in huntington's disease by up-regulating IRP1 expression.
    Niu L; Zhou Y; Wang J; Zeng W
    Metab Brain Dis; 2024 Apr; 39(4):559-567. PubMed ID: 38261161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
    Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
    Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
    Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
    J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
    Shekhar S; Vatsa N; Kumar V; Singh BK; Jamal I; Sharma A; Jana NR
    Hum Mol Genet; 2017 Jan; 26(2):420-429. PubMed ID: 28007908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
    Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
    J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alleviation of Huntington pathology in mice by oral administration of food additive glyceryl tribenzoate.
    Dutta D; Majumder M; Paidi RK; Pahan K
    Neurobiol Dis; 2021 Jun; 153():105318. PubMed ID: 33636386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
    Donley DW; Realing M; Gigley JP; Fox JH
    PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
    Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
    J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.